Table 1.

Body morphometry, laboratory data, and echocardiographic assessment of animals with left ventricular dysfunction following MI (treated vs. placebo)

	Placebo (n = 10)	GW501516 (n = 10)
Body weight (BW), g	29.3 ± 0.6	28 ± 1.1
Heart weight/BW, mg/g	5.9 ± 0.4	6.1 ± 0.5
Quadriceps weight/BW, mg/g	13.5 ± 0.8	12.9 ± 1.3
Glucose, mg/dl	167.4 ± 20.7	142.6 ± 8.7
Plasma FFA, pmol/μl	0.8 ± 0.1	0.58 ± 0.1
Plasma TAG, μg/μl	5.0 ± 0.4	3.02 ± 0.6
Quadriceps TAG, μg/mg	72.6 ± 5.4	100.2 ± 14.9
Echocardiographic analysis
FS% before intervention	18.5 ± 4.2	15.5 ± 3.5
FS% after intervention	20.6 ± 3.3	19.4 ± 3.7
HR before intervention, beats/min	431.4 ± 13	444.5 ± 12.2
HR after intervention, beats/min	423.7 ± 10	451.8 ± 11.3
AWT before intervention, mm	0.61 ± 0.04	0.67 ± 0.04
AWT after intervention, mm	0.72 ± 0.02	0.75 ± 0.03
PWT before intervention, mm	0.83 ± 0.06	0.78 ± 0.06
PWT after intervention, mm	0.76 ± 0.05	0.76 ± 0.07
LVESD before intervention, mm	4.17 ± 0.48	4.75 ± 0.45
LVESD after intervention, mm	4.22 ± 0.47	4.22 ± 0.48
LVEDD before intervention, mm	5.02 ± 0.34	5.56 ± 0.34
LVEDD after intervention, mm	5.27 ± 0.43	5.16 ± 0.38

Values are means ± SE. MI, myocardial infarction; FFA, free fatty acids; TAG, triacylglycerol; FS, fractional shortening; HR, heart rate; AWT, anterior wall thickness; PWT, posterior wall thickness; LVESD, left ventricular end-systolic diameter; LVEDD, left ventricular end-diastolic diameter.